Treatment patterns and best response in a contemporary cohort of patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion

被引：0
|
作者：
Lamanna, Nicole
Hurst, Deborah
Latremouille-Viau, Dominick
Ionescu-Ittu, Raluca
Guerin, Annie
Yim, Yeun Mi
Reyes, Carolina
机构：
[1] Herbert Irving Comprehens Canc Ctr, Hematol Malignancies Sect, New York, NY USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Anal Grp Inc, Montreal, PQ, Canada
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
175
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [31] The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients
    Tam, C. S.
    Wierda, W.
    O'Brien, S. M.
    Lerner, S.
    Abruzzo, L. V.
    Ferrajoli, A.
    Kantarjian, H. M.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
    O'Brien, Susan
    Jones, Jeffrey A.
    Coutre, Steven E.
    Mato, Anthony R.
    Hillmen, Peter
    Tam, Constantine
    Osterborg, Anders
    Siddiqi, Tanya
    Thirman, Michael J.
    Furman, Richard R.
    Ilhan, Osman
    Keating, Michael J.
    Call, Timothy G.
    Brown, Jennifer R.
    Stevens-Brogan, Michelle
    Li, Yunfeng
    Clow, Fong
    James, Danelle F.
    Chu, Alvina D.
    Hallek, Michael
    Stilgenbauer, Stephan
    LANCET ONCOLOGY, 2016, 17 (10): : 1409 - 1418
  • [33] The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 110 - 118
  • [34] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Schetelig, Johannes
    Coutre, Steven
    Seymour, John F.
    Munir, Talha
    Puvvada, Soham D.
    Wendtner, Clemens-Martin
    Roberts, Andrew W.
    Jurczak, Wojciech
    Mulligan, Stephen P.
    Boettcher, Sebastian
    Mobasher, Mehrdad
    Zhu, Ming
    Desai, Monali
    Chyla, Brenda
    Verdugo, Maria
    Enschede, Sari Heitner
    Cerri, Elisa
    Humerickhouse, Rod
    Gordon, Gary
    Hallek, Michael
    Wierda, William G.
    LANCET ONCOLOGY, 2016, 17 (06): : 768 - 778
  • [35] Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Veliz, Marays
    Pinilla-Ibarz, Javier
    CANCER CONTROL, 2012, 19 (01) : 37 - 53
  • [36] Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations
    Kim, Jinchul
    Cho, Jinhyun
    Lim, Joo Han
    Lee, Moon Hee
    BLOOD RESEARCH, 2025, 60 (01)
  • [37] How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam, Constantine S.
    Stilgenbauer, Stephan
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 587 - 593
  • [38] Incidence and outcome of chronic lymphocytic leukemia with deletion 17p: An Indian experience; challenges and opportunities
    Gogia, A.
    Kumar, L.
    Sharma, A.
    Gupta, R.
    Rani, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES
    Jones, J.
    Coutre, S.
    Byrd, J. C.
    Furman, R.
    Hillmen, P.
    Mato, A.
    Osterborg, A.
    Tam, C.
    Stilgenbauer, S.
    Wierda, W.
    Heerema, N.
    Eckert, K.
    Clow, F.
    Zhou, C.
    Chu, A.
    James, D.
    O'Brien, S.
    HAEMATOLOGICA, 2016, 101 : 150 - 150
  • [40] A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Mato, Anthony R.
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Zhang, Xiaojuan
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    HAEMATOLOGICA, 2022, 107 : 2630 - 2640
12345